FDA Orders JUUL to Stop Sales of E-Cigarettes

Jun.28.2022
The FDA has banned sales of Juul e-cigarettes due to lack of data on their potential health risks.

On Thursday, June 23rd, the US Food and Drug Administration (FDA) ordered American e-cigarette company JUUL to cease sales of its electronic cigarette products and remove them from store shelves. The reason behind such strict regulatory action by the FDA is the lack of data and evidence to evaluate the potential health risks associated with e-cigarettes. This ban is expected to have a significant impact on JUUL's revenue, with estimates suggesting a decrease of around 95%, essentially bringing the company back to its pre-launch state.

 

Following an order from the FDA, JUUL, a popular electronic cigarette brand among teenagers, must cease sales and distribution of its e-cigarette devices and four types of JUUL pods. However, this order does not prohibit consumers from owning or using JUUL products. The ban comes after an extensive review of JUUL, and all electronic cigarettes require FDA authorization to remain on the market. Prior to this, the FDA had already prohibited JUUL from selling all sweet and fruity flavored e-cigarette pods.

 

Although this is a regulatory event regarding electronic cigarettes that occurred in the United States, it is expected to have significant impacts on the entire e-cigarette market. These impacts will primarily manifest in three areas.

 

Firstly, the strict regulation of electronic cigarettes is set to become a consensus. Regulatory authorities, led by the US FDA, have begun to focus on regulating and strengthening the oversight of electronic cigarettes. This signals that electronic cigarettes will become the focus of regulatory oversight and restructuring in various countries worldwide.

 

The core reason why the United States has started to strictly regulate and overhaul electronic cigarettes is due to the fact that after tracking and reviewing them, it was found that there was no effective data to prove their impact on health and risk. In other words, the current claims that electronic cigarettes are healthier or less harmful than traditional cigarettes cannot be supported by scientific data or evidence. This means that the notion of electronic cigarettes causing only minimal harm is actually nothing more than a marketing concept.

 

Furthermore, the health hazards behind the sugar coating cannot be ignored. Taste has long been the golden vein of electronic cigarettes, with flavored products making up nearly 90% of the market share. Currently, there are approximately 16,000 flavored electronic cigarette products on the market, including fruity, candy, and dessert flavors.

 

As a result, the demographic that tends to choose e-cigarettes is largely composed of young people. They are looking for the addictive experience that some elements of cigarettes offer, as well as the better taste and more trendy feel that e-cigarettes provide. This is not just true in our country, as the State Tobacco Monopoly Administration has released national standards and regulations for e-cigarettes, which forbid the sale of flavored e-cigarettes that are not tobacco-flavored, as well as e-cigarettes that allow users to add their own vaping substances.

 

After these additives are banned, electronic cigarettes will lose their competitive advantage over traditional cigarettes. In addition, without improved taste and better control over health risks, it remains uncertain whether the release of concentrated e-liquids through electronic technology is more or less harmful.

 

Finally, with the loss of the gray area, which is to say that additives have always been the core competitiveness of e-cigarettes because it was a gray area. For e-cigarette manufacturers, they would typically make subtle changes to additives to increase the addictive and dependent nature for consumers. However, with the clear ban on additives, this means that e-cigarettes are losing their competitive advantage and core competitiveness.

 

Not only has the electronic cigarette lost its competitive edge, but it also does not have a better taste or lower health risks compared to traditional cigarettes. Of course, the manufacturers of electronic cigarettes will not admit to any health risks associated with their product. However, the FDA has made it clear that there is no scientific evidence proving that electronic cigarettes pose less of a health risk than traditional cigarettes.

 

The future of electronic cigarettes is a question facing manufacturers, especially as overall societal health awareness increases. The behavior and industry, which pose significant health risks to humans, may not necessarily exit the stage of human society but will likely face increasingly stringent regulations.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product: Tyson 2.0 Launches Nicotine Pouches in the U.S. with Boxing-Inspired Flavors
Product: Tyson 2.0 Launches Nicotine Pouches in the U.S. with Boxing-Inspired Flavors
Boxing legend Mike Tyson’s brand TYSON 2.0 has launched a new line of nicotine pouches, now available in the U.S. through distributors like VapeSourcing at a wholesale price of $3.99 per pack. Each pack contains 15 pouches and comes in four boxing-themed flavors with nicotine strengths of 4mg, 6mg, and 10mg.
Jul.08 by 2FIRSTS.ai
Australian Police Probe Illegal Vaping Network, Freeze $680,000 in Assets
Australian Police Probe Illegal Vaping Network, Freeze $680,000 in Assets
Australia’s AFP, in “Operation Smoke Storm,” froze over AUD 1 million ($680,000) tied to illegal vape sales. Online-branded e-cigarettes and transaction records were seized; funds may support community crime prevention.
Jul.14 by 2FIRSTS.ai
Bangladesh Supreme Court Rejects Lease Appeal, British American Tobacco to Close Dhaka Factory
Bangladesh Supreme Court Rejects Lease Appeal, British American Tobacco to Close Dhaka Factory
British American Tobacco Bangladesh (BAT) will relocate its headquarters from Mohakhali to Ashulia in mid-2025 after the Supreme Court rejected its appeal to extend the Dhaka camp land lease. The move includes the closure of the 61-year-old Dhaka factory. BAT plans a smooth transition and reported a strong Q1 2025 performance of BDT 95.97 billion ($800 million).
Jun.23 by 2FIRSTS.ai
UK Releases Latest Approved E-cigarette List: 227 New SKUs Cleared, Including ELFBAR, LOST MARY, and VAPORESSO
UK Releases Latest Approved E-cigarette List: 227 New SKUs Cleared, Including ELFBAR, LOST MARY, and VAPORESSO
Between July 19 and 28, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published 227 SKUs in its e-cigarette product notification database, including updates on high-puff devices, refillable pods, and multi-flavor cartridges from brands such as ELFBAR, LOST MARY, and VAPORESSO.
Jul.28 by 2FIRSTS.ai
Thai PM’s Secretary: Government to Announce Results of Crackdown on Illegal E-Cigarettes
Thai PM’s Secretary: Government to Announce Results of Crackdown on Illegal E-Cigarettes
The Thai prime minister’s secretary has revealed the government will soon announce progress in cracking down on illegal e-cigarettes and plans to leverage AI to enhance public communications. Dr. Prommin Lertsuridej, secretary-general to the prime minister, stressed the need to recalibrate PR strategies to better address public concerns.
Jul.15 by 2FIRSTS.ai
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
The U.S. Food and Drug Administration has officially launched Elsa, a generative AI tool designed to speed up clinical reviews, internal writing, and data processing tasks. After successful pilots across multiple departments, Elsa is now being rolled out agency-wide.
Jun.04 by 2FIRSTS.ai